Candel Therapeutics, Inc.
CADLNext catalyst
NDA Filing
Get an email about CADL's next catalysts
Track Candel Therapeutics (CADL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (earnings, Phase 2 readout, PDUFA date).See the timeline
4 upcoming, 0 past
CADL Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.30 | FQ end Sep/2026 | Call: tbd
NDA Filing
Candel Therapeutics is targeting a prostate cancer regulatory filing in 2026 while advancing its lung cancer study program. The company is progressing its pipeline with plans to submit for approval in the near-term future.
Sourceaglatimagene besadenovec + valacyclovir Phase 2 Est. Readout
Estimated primary completion for aglatimagene besadenovec + valacyclovir trial (NCT07332000) in Prostate Cancer Patients Treated by Radiotherapy. Topline data typically follows completion by weeks to months.
SourceFDA PDUFA Date
For prostate cancer. BLA submitted. AI-extracted from: CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug
SourceHow CADL's past catalysts played out
Market Overview
Stock performance and key metrics
aglatimagene besadenovec
Prostate Cancer
Valacyclovir
Non-squamous, Non-Small Cell Lung Cancer
aglatimagene besadenovec + valacyclovir
Prostate Cancer Patients Treated by Radiotherapy
CAN-2409
Malignant Glioma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
aglatimagene besadenovec | Phase 3 | Prostate Cancer | - | - |
Valacyclovir | Phase 3 | Non-squamous, Non-Small Cell Lung Cancer | - | - |
aglatimagene besadenovec + valacyclovir | Phase 3 | Prostate Cancer Patients Treated by Radiotherapy | - | - |
CAN-2409 | Phase 2 | Malignant Glioma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Candel Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Candel Therapeutics, Inc.'s (CADL) pipeline across Phase 3, Phase 2. Its lead program is aglatimagene besadenovec (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Candel Therapeutics, Inc.'s next FDA catalyst?→
Candel Therapeutics, Inc.'s (CADL) next tracked catalyst is an NDA filing expected Dec 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CADL biotech catalysts?→
Add CADL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Candel Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.